Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1046361 | 0.98 | CYP1A2 (0.55) | CYP1A2CYP2D6ALDH1A1TSHR | |
| Hydrochloric Acid SCHEMBL10619074 | 0.85 | CYP1A2 (0.57) | CYP1A2CYP2D6ALDH1A1TSHRDNM1 | |
| SCHEMBL3275536 | 0.82 | CYP1A2 (0.59) | CYP1A2CYP2D6ALDH1A1TSHRDNM1 | |
| Hydrochloric Acid SCHEMBL4292279 | 0.81 | CYP1A2 (0.53) | CYP1A2CYP2D6ALDH1A1TSHRDNM1 | |
| Hydrochloric Acid SCHEMBL3915191 | 0.80 | CYP1A2 (0.56) | CYP1A2CYP2D6ALDH1A1TSHRDNM1 | |
| SCHEMBL3832951 | 0.78 | CYP1A2 (0.58) | CYP1A2CYP2D6ALDH1A1TSHRDNM1 | |
| SCHEMBL3830223 | 0.77 | CYP1A2 (0.82) | CYP1A2CYP2D6ALDH1A1TSHRDNM1 | |
| Hydrochloric Acid SCHEMBL28536401 | 0.76 | CYP1A2 (0.51) | CYP1A2CYP2D6DNM1 | |
| Hydrochloric Acid SCHEMBL29150638 | 0.76 | CYP1A2 (0.47) | CYP1A2CYP2D6ALDH1A1 | |
| Hydrochloric Acid SCHEMBL381021 | 0.74 | CYP1A2 (0.63) | CYP1A2CYP2D6ALDH1A1TSHRDNM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 103 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210300917-A1 | Solid State Forms of an Apoptosis-Inducing Agent and Processes Thereof | LUPIN LTD (IN) | 2021-09-30 | — | — | US | claimed |
| WO-2018104953-A1 | IMPROVED PROCESS FOR THE PREPARATION OF 7-{4-[4-(2,3-DICHLOROPHENYL)-PIPERAZIN-1-YL]BUTOXY}-2OXO-3,4-DIHYDRO-2H-QUINOLIN-1-YL)METHYL DODECANOATE | MSN LABORATORIES PRIVATE LIMITED, R&D CENTER (IN) | 2018-06-14 | — | — | WO | claimed |
| EP-0189305-A2 | Peptide derivatives | ICI AMERICAS INC. (US) | 1986-07-30 | — | — | EP | claimed |
| US-20260079155-A1 | FABRICATION OF FLUORESCENT NANOPARTICLES AND THEIR CONJUGATES FOR IN VITRO AND IN VIVO DIAGNOSTICS | AUISET BIOTECHNOLOGY CO LTD (CN) | 2026-03-19 | — | — | US | disclosed |
| US-20250325186-A1 | Implantable Imagers for in Vivo Imaging | UNIV CALIFORNIA (US) | 2025-10-23 | — | — | US | disclosed |
| US-12384748-B2 | Modulators of mas-related g-protein receptor X2 and related products and methods | ESCIENT PHARMACEUTICALS, INC. (US) | 2025-08-12 | — | — | US | disclosed |
| US-20240393323-A1 | Microfluidic Magnetic Separation Device with A Magnetophoretic Gradient for Isolation of Target Cell Populations from Fluid Samples | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2024-11-28 | — | — | US | disclosed |
| US-20240351987-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X2 AND RELATED PRODUCTS AND METHODS | ESCIENT PHARMACEUTICALS INC (US) | 2024-10-24 | — | — | US | disclosed |
| US-20240336570-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X2 AND RELATED PRODUCTS AND METHODS | ESCIENT PHARMACEUTICALS INC (US) | 2024-10-10 | — | — | US | disclosed |
| US-20240239749-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X2 AND RELATED PRODUCTS AND METHODS | ESCIENT PHARMACEUTICALS INC (US) | 2024-07-18 | — | — | US | disclosed |
| WO-2024118297-A1 | BIOPROSTHETIC TISSUE AND PROSTHETIC ANTIMICROBIAL TREATMENT | EDWARDS LIFESCIENCES CORPORATION (US) | 2024-06-06 | — | — | WO | disclosed |
| EP-0635014-A1 | INDOLE DERIVATIVES AS 5-HT1-LIKE AGONISTS. | PFIZER LTD (GB) | 1995-01-25 | — | — | EP | disclosed |
| US-5310922-A | Squaraine dyes | SYNTEX (U.S.A.) INC. (US) | 1994-05-10 | — | — | US | disclosed |
| EP-0567026-A1 | 4,1-Benzoxazepin derivatives as squalene synthase inhibitors and their use in the treatment of hypercholesteremia and as fungicides | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1993-10-27 | — | — | EP | disclosed |
| EP-0526649-A1 | CARBOXYMETHYLMANNOGLUCAN AND DERIVATIVE THEREOF | DRUG DELIVERY SYSTEM INSTITUTE, LTD. (JP) | 1993-02-10 | — | — | EP | disclosed |
| EP-0149593-B1 | NOVEL THIOPEPTOLIDE SUBSTRATES FOR VERTEBRATE COLLAGENASE | Monsanto Company (US) | 1990-03-28 | — | — | EP | disclosed |
| EP-0284632-A1 | Phenylalanine derivative and proteinase inhibitor | Okamoto, Shosuke (JP) | 1988-10-05 | — | — | EP | disclosed |
| EP-0244836-A2 | Tripeptide derivatives | Dainippon Pharmaceutical Co., Ltd. (JP) | 1987-11-11 | — | — | EP | disclosed |
| EP-0238319-A1 | Pyrrolidine derivatives | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1987-09-23 | — | — | EP | disclosed |
| EP-0117053-A1 | Azetidinone derivatives | AJINOMOTO CO., INC. (JP) | 1984-08-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240351987-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X2 AND RELATED PRODUCTS AND METHODS | MRGPRX2, MRGPRX1, MRGPRX4 | CYP1A2 3308/4885CYP2D6 2509/4885ALDH1A1 4827/4885 |
| US-20260079155-A1 | FABRICATION OF FLUORESCENT NANOPARTICLES AND THEIR CONJUGATES FOR IN VITRO AND IN VIVO DIAGNOSTICS | NDC1, IK, SAMM50 | CYP1A2 1258/4885CYP2D6 2006/4885ALDH1A1 80/4885 |
| US-20240239749-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X2 AND RELATED PRODUCTS AND METHODS | MRGPRX2, MRGPRX1, MRGPRX4 | CYP1A2 3460/4885CYP2D6 2689/4885ALDH1A1 4780/4885 |
| US-20240336570-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X2 AND RELATED PRODUCTS AND METHODS | MRGPRX2, MRGPRX1, MRGPRX4 | CYP1A2 3301/4885CYP2D6 2647/4885ALDH1A1 4805/4885 |
| US-20210300917-A1 | Solid State Forms of an Apoptosis-Inducing Agent and Processes Thereof | BAX, BCL2, BAD | CYP1A2 2565/4885CYP2D6 2441/4885ALDH1A1 2907/4885 |
| US-12384748-B2 | Modulators of mas-related g-protein receptor X2 and related products and methods | MRGPRX2, MRGPRX1, MRGPRX4 | CYP1A2 3308/4885CYP2D6 2509/4885ALDH1A1 4827/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.